Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Hellenic Cooperative Oncology Group

Status: Active, not recruiting

Conditions: Ovarian Cancer

Treatments: Drug: PARP inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT04724031

P420_PARP

Details and patient eligibility

About

Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.

Full description

A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.

Enrollment: 150 estimated patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• women >18 years old with advanced high grade ovarian cancer

Exclusion criteria

Trial design

150 participants in 1 patient group

One cohort

Description:

women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment

Treatment:

Drug: PARP inhibitor